Also known as: Lenvima
Lenvatinib is a multi-receptor tyrosine kinase inhibitor marketed as Lenvima for multiple solid tumor indications. It is used in thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma, often in combination regimens. The FDA first approved Lenvima on February 13, 2015.
Medivir's 2025 Annual Report highlights FDA Orphan Drug Designation for MIV-711 in Osteogenesis Imperfecta and promising fostrox liver cancer data showing 13.7-month median survival. The company raised SEK 196 million to fund Phase 2 studies for both programs and reported year-end cash of SEK 119.2 million.
DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
The 2026 ASCO GU Symposium featured significant trial results in renal cell carcinoma, urothelial carcinoma, and prostate cancer, including data from LITESPARK-022, KEYNOTE-B15, SunRISE-2, and PEACE-3 studies.
Phase III trial demonstrates belzutifan plus lenvatinib significantly improved progression-free survival versus cabozantinib in previously treated renal cell carcinoma patients, while neoadjuvant studies show promise for locally advanced disease.
Nivolumab plus ipilimumab demonstrates survival benefits in unresectable hepatocellular carcinoma but exceeds US cost-effectiveness thresholds at current pricing, with extended dosing intervals or price reductions needed for economic viability.
Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07594015 |
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy |
RECRUITING | PHASE2 |
| NCT07571551 |
Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma |
RECRUITING | PHASE2 |
| NCT07537985 |
Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment |
COMPLETED | NA |
| NCT07537946 |
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07518706 |
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin |
NOT_YET_RECRUITING | PHASE2 |
| NCT07495579 |
Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07493668 |
Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy |
RECRUITING | PHASE2 |
| NCT07487662 |
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk |
NOT_YET_RECRUITING | PHASE2 |
| NCT07475026 |
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence |
NOT_YET_RECRUITING | PHASE3 |
| NCT07466225 |
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion |
NOT_YET_RECRUITING |
